Celcuity Inc Dossier - Source-backed chat

Celcuity Inc

CELCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.47

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $75.13Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $3.7B

Enterprise Value $3.5B

Shares Outstanding 48.9M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Celcuity is transitioning from a clinical-stage biotechnology company to a commercial-stage oncology player, driven by its lead candidate gedatolisib. Gedatolisib is a potential first-in-class, multi-target PI3K/AKT/mTOR (PAM) inhibitor that comprehensively blockades the pathway. The company has achieved positive Phase 3 VIKTORIA-1 results in both PIK3CA wild-type and mutant cohorts of HR+/HER2- advanced breast cancer. With an upcoming FDA PDUFA date of July 17, 2026, for the wild-type cohort and a planned sNDA for the mutant cohort, Celcuity is positioned for a near-term commercial launch. The recent $500 million convertible notes offering significantly strengthens its balance sheet, extending its cash runway through 2027 and fully funding launch preparations.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$140.00

Mean target$160.64

High · most bullish analyst$178.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$140.00

The FDA issues a Complete Response Letter (CRL) or delays the approval of gedatolisib due to manufacturing, safety, or clinical data queries. Commercial launch is postponed, increasing the cash burn rate and forcing the company to seek additional capital under less favorable market conditions. Clinical development of gedatolisib in other indications, such as prostate cancer, faces delays.

Base CaseCentral scenario

$160.64

Matches the consensus mean

Gedatolisib receives FDA approval for the PIK3CA wild-type cohort in Q3 2026, and the company successfully submits the sNDA for the mutant cohort. Commercial launch proceeds as planned, with steady market penetration in the second-line setting. The company's cash reserves are sufficient to support operations and commercialization expenses through 2027 without requiring immediate dilutive equity financing.

Bull CaseUpside scenario

$178.00

The FDA approves gedatolisib on or before the July 17, 2026 PDUFA date, followed by a rapid sNDA submission and approval for the PIK3CA mutant cohort. Commercial uptake is strong, driven by gedatolisib's superior efficacy and differentiated safety profile (intravenous administration avoiding the severe toxicities of oral PI3K inhibitors). Global partnerships are secured in Europe and Asia, unlocking non-dilutive milestone payments and expanding the addressable market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated mechanism of action: Gedatolisib targets all four Class I PI3K isoforms and both mTOR complexes (mTORC1/2), offering a more comprehensive blockade than single-target inhibitors.
Positive Phase 3 data: The VIKTORIA-1 trial met its primary endpoints in both the PIK3CA wild-type and mutant cohorts, demonstrating clinically meaningful improvements in progression-free survival.
Strong balance sheet: The June 2026 upsized public offering of $500 million in convertible senior notes provides substantial capital to repay existing debt and fund commercial launch activities.

Key Investment Risks

Regulatory risk: Any delay or rejection by the FDA regarding the NDA for gedatolisib would severely impact the company's valuation and commercial timeline.
Commercial execution risk: As a clinical-stage company transitioning to commercialization, Celcuity must successfully build out its sales and marketing infrastructure to compete with established oncology players.
High cash burn: Late-stage clinical trials (such as VIKTORIA-2) and commercial launch preparations require significant capital, which could lead to future dilution if commercial revenues ramp up slowly.

Thesis Invalidation Triggers

FDA issuance of a Complete Response Letter (CRL) or significant delay in the approval of gedatolisib beyond Q3 2026.
Severe safety signals or adverse events emerging during the ongoing VIKTORIA-2 or CELC-G-201 clinical trials.
Failure to secure a commercial partner for European or global markets, increasing the financial burden of international expansion.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.